| Platelets promote metastasis via binding tumor CD97 leading to bidirectional signaling that coordinates transendothelial migration Y Ward, R Lake, F Faraji, J Sperger, P Martin, C Gilliard, KP Ku, ... Cell reports 23 (3), 808-822, 2018 | 128 | 2018 |
| AXL mediates cetuximab and radiation resistance through tyrosine 821 and the c-ABL kinase pathway in head and neck cancer NK McDaniel, M Iida, KP Nickel, CA Longhurst, SR Fischbach, ... Clinical Cancer Research 26 (16), 4349-4359, 2020 | 37 | 2020 |
| Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma RM Bade, JL Schehr, H Emamekhoo, BK Gibbs, TS Rodems, ... Molecular oncology 15 (9), 2330-2344, 2021 | 19 | 2021 |
| Reversible epigenetic alterations regulate class I HLA loss in prostate cancer TS Rodems, E Heninger, CN Stahlfeld, CS Gilsdorf, KN Carlson, ... Communications Biology 5 (1), 897, 2022 | 17 | 2022 |
| Live cell molecular analysis of primary prostate cancer organoids identifies persistent androgen receptor signaling E Heninger, D Kosoff, TS Rodems, N Sethakorn, A Singh, H Gungurthi, ... Medical Oncology 38, 1-13, 2021 | 10 | 2021 |
| Platelets promote metastasis via binding tumor CD97 leading to bidirectional signaling that coordinates transendothelial migration. Cell Rep 23: 808–822 Y Ward, R Lake, F Faraji, J Sperger, P Martin, C Gilliard, KP Ku, ... | 7 | 2018 |
| Adaptive responses to antibody based therapy TS Rodems, M Iida, TM Brand, HE Pearson, RA Orbuch, BG Flanigan, ... Seminars in Cell & Developmental Biology 50, 153-163, 2016 | 6 | 2016 |
| SEEMLIS: a flexible semi-automated method for enrichment of methylated DNA from low-input samples TS Rodems, DS Juang, CN Stahlfeld, CS Gilsdorf, TEG Krueger, ... Clinical Epigenetics 14 (1), 37, 2022 | 4 | 2022 |
| Development and clinical validation of circulating tumor cell (CTC) biomarkers in clear cell renal cell carcinoma (ccRCC) for the OMNIVORE clinical trial. W Arafat, J Desotelle, T Rodems, RR McKay, J Abel, TK Choueiri, ... Journal of Clinical Oncology 35 (15_suppl), 4579-4579, 2017 | 2 | 2017 |
| Abstract A128: AXL mediates cetuximab resistance through tyrosine 821 and activation of c-Abl kinase in head and neck cancer NK McDaniel, M Iida, KP Nickel, TS Rodems, AD Swick, PJ Prabakaran, ... Molecular Cancer Therapeutics 18 (12_Supplement), A128-A128, 2019 | 1 | 2019 |
| Discovery of ETX-19477, a novel and selective PARG inhibitor with high potency against tumors with underlying replication stress JP Holleran, TS Rodems, S Sharma, AM Santini, C Wuerz, J Liu, L Tian, ... Cancer Research 84 (6_Supplement), 2083-2083, 2024 | | 2024 |
| Volume-free reagent addition and exclusion-based sample preparation for streamlined multi-step assays DJ Beebe, JM Lang, DS Juang, SM Berry, TS Rodems US Patent 11,618,021, 2023 | | 2023 |
| Epigenetically Silenced Class I Human Leukocyte Antigen (HLA-I): A Novel Biomarker and Therapeutic Target in Prostate Cancer TS Rodems The University of Wisconsin-Madison, 2020 | | 2020 |
| Epigenetic Analysis of Circulating Tumor Cells T Rodems, University of Wisconsin Madison United States | | 2018 |
| Targeting TAM family members with antibody or small molecule inhibitors enhances therapeutic modalities of HNSCC NK Black, M Iida, TS Rodems, TM Brand, RJ Kimple, DL Wheeler Cancer Research 77 (13_Supplement), 4176-4176, 2017 | | 2017 |
